Improved radiosynthesis of the apoptosis marker 18F-ICMT11 including biological evaluation.
We improved the specific radioactivity of the apoptosis imaging isatin derivative (18)F-ICMT11. We then evaluated (18)F-ICMT11 in EL4 tumor-bearing mice 24h after treatment with etoposide/cyclophosphamide combination therapy. Dynamic PET imaging demonstrated increased uptake in the drug-treated (0.115±0.011 SUV) compared to the vehicle-treated EL4 tumors (0.083±0.008 SUV). This effect correlated to the observed increases in apoptotic index.
MDx Discovery (Part of GE Healthcare), Hammersmith Imanet Ltd, Hammersmith Hospital, London, United Kingdom. matthias.glaser@ge.com
Matthias
M
Glaser
Julian
J
Goggi
Graham
G
Smith
Matthew
M
Morrison
Sajinder K
SK
Luthra
Edward
E
Robins
Eric O
EO
Aboagye
D000818:Animals; D017209:Apoptosis; D001386:Azides / Q000138:chemical synthesis* / Q000737:chemistry; D015415:Biomarkers / Q000737:chemistry*; D003952:Diagnostic Imaging; D004195:Disease Models, Animal; D019788:Fluorodeoxyglucose F18; D007211:Indoles / Q000138:chemical synthesis* / Q000737:chemistry; D007510:Isatin / Q000737:chemistry; D008223:Lymphoma / Q000000981:diagnostic imaging*; D051379:Mice; D015394:Molecular Structure; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000138:chemical synthesis* / Q000737:chemistry
C571272:(18)F-ICMT11; D001386:Azides; D015415:Biomarkers; D007211:Indoles; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D007510:Isatin